We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
For the quarter ended June 2025, Alnylam Pharmaceuticals (ALNY - Free Report) reported revenue of $773.69 million, up 17.3% over the same period last year. EPS came in at $0.32, compared to $0.56 in the year-ago quarter.
The reported revenue represents a surprise of +14.96% over the Zacks Consensus Estimate of $673 million. With the consensus EPS estimate being -$0.03, the EPS surprise was +1166.67%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Product revenues, net: $672.21 million versus the 11-analyst average estimate of $540.14 million. The reported number represents a year-over-year change of +63.9%.
Revenues- Royalty revenue: $39.98 million versus the nine-analyst average estimate of $32.74 million. The reported number represents a year-over-year change of +78.5%.
Net Product Revenue- Oxlumo: $46.87 million versus $46.64 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +15.4% change.
Revenues- Net revenues from research collaborators: $61.5 million versus $90.07 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -73% change.
Net Product Revenue- Givlaari: $80.85 million compared to the $72.59 million average estimate based on nine analysts. The reported number represents a change of +30.1% year over year.
Net Product Revenue- Amvuttra: $491.95 million versus $365.41 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +113.8% change.
Net Product Revenue- Onpattro: $52.24 million compared to the $45.89 million average estimate based on eight analysts. The reported number represents a change of -32.4% year over year.
Net revenues from research collaborators- Other: $10.69 million versus $3 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +872.4% change.
Net revenues from research collaborators- Regeneron Pharmaceuticals: $32.54 million versus $17.5 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -84.3% change.
Net revenues from research collaborators- Roche: $18.27 million compared to the $12 million average estimate based on two analysts. The reported number represents a change of +10.7% year over year.
Shares of Alnylam have returned +3% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2025, Alnylam Pharmaceuticals (ALNY - Free Report) reported revenue of $773.69 million, up 17.3% over the same period last year. EPS came in at $0.32, compared to $0.56 in the year-ago quarter.
The reported revenue represents a surprise of +14.96% over the Zacks Consensus Estimate of $673 million. With the consensus EPS estimate being -$0.03, the EPS surprise was +1166.67%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Alnylam here>>>
Shares of Alnylam have returned +3% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.